GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Prescient Therapeutics Ltd (FRA:UDD) » Definitions » YoY EPS Growth

Prescient Therapeutics (FRA:UDD) YoY EPS Growth : 0.00% (As of Dec. 2023)


View and export this data going back to 2006. Start your Free Trial

What is Prescient Therapeutics YoY EPS Growth?

YoY EPS Growth is the percentage change of Earnings per Share (Diluted) over the past twelve months. Prescient Therapeutics's YoY EPS Growth for the quarter that ended in Dec. 2023 was 0.00%.

Prescient Therapeutics's Earnings per Share (Diluted) for the six months ended in Dec. 2023 was €0.00.

Prescient Therapeutics YoY EPS Growth Historical Data

The historical data trend for Prescient Therapeutics's YoY EPS Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Prescient Therapeutics YoY EPS Growth Chart

Prescient Therapeutics Annual Data
Trend Jun13 Jun14 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
YoY EPS Growth
Get a 7-Day Free Trial Premium Member Only Premium Member Only -25.00 50.00 100.00 - -

Prescient Therapeutics Semi-Annual Data
Dec13 Jun14 Dec14 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
YoY EPS Growth Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 100.00 - - - -

Prescient Therapeutics YoY EPS Growth Calculation

YoY EPS Growth is the percentage change of Earnings per Share (Diluted) over the past twelve months.

Prescient Therapeutics's YoY EPS Growth for the fiscal year that ended in Jun. 2023 is calculated as:

YoY EPS Growth (A: Jun. 2023 )
=(Earnings per Share (Diluted) (A: Jun. 2023 )-Earnings per Share (Diluted) (A: Jun. 2022 ))/ | Earnings per Share (Diluted) (A: Jun. 2022 ) |
=(0-0)/ | 0 |
=N/A %

Prescient Therapeutics's YoY EPS Growth for the quarter that ended in Dec. 2023 is calculated as:

YoY EPS Growth (Q: Dec. 2023 )
=(Earnings per Share (Diluted) (Q: Dec. 2023 )-Earnings per Share (Diluted) (Q: Dec. 2022 )) / | Earnings per Share (Diluted) (Q: Dec. 2022 )) |
=(0-0)/ | 0 |
=N/A %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Prescient Therapeutics YoY EPS Growth Related Terms

Thank you for viewing the detailed overview of Prescient Therapeutics's YoY EPS Growth provided by GuruFocus.com. Please click on the following links to see related term pages.

Prescient Therapeutics (FRA:UDD) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Prescient Therapeutics Ltd (FRA:UDD) » Definitions » YoY EPS Growth
Comparable Companies
ASX:EZZ ASX:CYP ASX:LTP ASX:ATH ASX:BIT ASX:ADO ASX:SPL ASX:CHM ASX:IMC ASX:RAD OCSE:NOVO B VRTX REGN ASX:CSL MRNA XKRX:207940 XKRX:068270 XBRU:UCB XBRU:ARGX BNTX
Traded in Other Exchanges
PTX:Australia
Address
Level 4, 100 Albert Road, South Melbourne, Melbourne, VIC, AUS, 3205
Website
https://www.ptxtherapeutics.com
Prescient Therapeutics Ltd is a clinical-stage oncology company. The company develops novel compounds for the treatment of a range of cancers in Australia. Its product in the pipeline includes OmniCAR; PTX-100 and PTX-200. OmniCAR is a universal immune receptor platform enabling controllable T-cell activity and multi-antigen targeting with a single cell product.

Prescient Therapeutics (FRA:UDD) Headlines

No Headlines